Organization | Robert Wood Johnson Foundation

Robert Wood Johnson Foundation Report issue

Foundation Phase 4

Founded: Princeton NJ United States (1972)

Organization Overview

First Clinical Trial

2004

NCT00565916

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Robert Wood Johnson Foundation

Active Ingredients

Drugs in Phase 4 Trials (4)

bupropion (wellbutrin) (3 trials)

chlorhexidine (hibitane) (1 trial)

mupirocin (bactroban) (1 trial)

nicotine (nicorette) (1 trial)

Drugs in Other Trials (8)

aripiprazole (abilify) (1 trial)

curcumin (1 trial)

eplerenone (inspra) (1 trial)

estrogen (1 trial)

fluoxetine (prozac) (1 trial)

lamotrigine (lamictal) (1 trial)

progesterone (progestasert) (1 trial)

sertraline (zoloft) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Tobacco Use Disorder (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 7
# of Trial APIs: 12